Biogen Inc. $BIIB Stock: Prime Capital Investment Advisors LLC Raises Stake

Key Points

• Prime Capital Investment Advisors increased its Biogen stake by 776.4% in the third quarter, holding 21,271 shares valued at approximately $4.8 million. Institutional investors collectively own 87.93% of the company.
• Analyst sentiment remains favorable, with Biogen receiving a consensus “Moderate Buy” rating and an average price target of $239.96, while several firms recently raised their targets or issued buy and outperform ratings.
• Biogen reported quarterly earnings of $3.60 per share, exceeding expectations, with revenue of $2.74 billion. Its stock opened at $243.10, near its 52-week high, as investors weigh growth prospects from its nephrology portfolio and pipeline.

Prime Capital Investment Advisors LLC lifted its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 776.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,271 shares of the biotechnology company's stock after purchasing an additional 18,844 shares during the period. Prime Capital Investment Advisors LLC's holdings in Biogen were worth $4,805,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Biogen in the 2nd quarter worth $3,453,878,000. Primecap Management Co. CA bought a new position in shares of Biogen during the 2nd quarter worth $3,274,304,000. Wellington Management Group LLP increased its stake in shares of Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company's stock valued at $673,560,000 after buying an additional 155,828 shares during the period. Amundi increased its stake in shares of Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company's stock valued at $327,727,000 after buying an additional 726,004 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of Biogen during the second quarter valued at $322,640,000. Institutional investors own 87.93% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BIIB. Guggenheim upped their price objective on shares of Biogen from $260.00 to $280.00 and gave the stock a "buy" rating in a research note on Tuesday, July 21st. UBS Group increased their target price on shares of Biogen from $240.00 to $270.00 and gave the stock a "buy" rating in a report on Friday, October 9th. Wall Street Zen downgraded shares of Biogen from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Seaport Research Partners raised shares of Biogen to an "outperform" rating in a research report on Monday, October 12th. Finally, Jefferies Financial Group restated a "buy" rating on shares of Biogen in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Biogen currently has a consensus rating of "Moderate Buy" and a consensus target price of $239.96.

Biogen Trading Up 4.1%

Shares of NASDAQ BIIB opened at $243.10 on Wednesday. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $244.65. The business has a fifty day moving average price of $221.28 and a 200 day moving average price of $204.74. The stock has a market capitalization of $35.92 billion, a P/E ratio of 43.03, a price-to-earnings-growth ratio of 2.60 and a beta of 0.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion for the quarter, compared to analysts' expectations of $2.46 billion. During the same period last year, the business earned $5.47 EPS. The company's revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts expect that Biogen Inc. will post 12.31 EPS for the current fiscal year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen announced that 76-week EMPAVELI® (pegcetacoplan) data to be presented at ASN Kidney Week showed sustained proteinuria reduction, continued stabilization of kidney function and a consistent long-term safety profile in patients with C3G and primary IC-MPGN. The data supports the commercial potential of EMPAVELI following its expanded FDA approval. Biogen nephrology data announcement
• Positive Sentiment: The company is highlighting a broader nephrology strategy, including investigational felzartamab programs in antibody-mediated rejection, IgA nephropathy and membranous nephropathy. Investors may view these programs, along with the Apellis acquisition, as potential sources of growth and earnings accretion beginning in 2027. Biogen kidney-disease data and pipeline analysis
• Positive Sentiment: Wells Fargo raised its Biogen price target from $250 to $310 and maintained an “overweight” rating, reinforcing bullish sentiment toward the company’s pipeline and longer-term growth outlook.
• Positive Sentiment: Recent analyst coverage remains constructive, with Needham, Evercore ISI and Guggenheim issuing buy or outperform ratings. Institutional ownership was also mixed but leaned positive, with more investors adding shares than reducing positions in the latest reported quarter.
• Neutral Sentiment: Investors are likely positioning ahead of Biogen’s third-quarter 2026 earnings report and webcast scheduled for October 28, which could provide updates on EMPAVELI sales, the Apellis integration and full-year expectations.
• Negative Sentiment: Valuation indicators provide a counterpoint: GuruFocus’ estimated GF Value of $202.16 is below the referenced market price, while the median analyst price target of $223.50 is also lower. EMPAVELI carries a boxed warning for serious infections and requires a REMS program, potentially limiting adoption.
• Negative Sentiment: Biogen insider activity has been unfavorable, with two reported insider sales and no purchases during the past six months. Felzartamab also remains investigational, so its projected contribution depends on future clinical and regulatory success.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.